Sahebkar Amirhossein, Reiner Željko, Almahmeed Wael, Jamialahmadi Tannaz, Simental-Mendía Luis E
Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Cardiovasc Drugs Ther. 2024 Oct 28. doi: 10.1007/s10557-024-07634-5.
The goal of this meta-analysis was to establish whether statin treatment reduces Lp-PLA2 mass concentration and/or activity.
PubMed, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar databases were searched using MESH terms and keywords. Randomized controlled trials (RCT) with either parallel or cross-over design examining the effect of statins on Lp-PLA2 mass and/or activity were included in meta-analysis.
Out of 256 articles, 10 RCT were selected for meta-analysis. Statin therapy significantly reduced both Lp-PLA2 mass (WMD -44.46 ng/mL; 95%CI -59.01, -29.90; p < 0.001; I = 93%) and activity (WMD -39.37 nmol/min/mL; 95%CI -69.99, -8.75; p = 0.01; I = 100%). The sensitivity analysis was robust for Lp-PLA2 mass and was also positive for two studies concerning Lp-PLA2 activity.
Statin therapy significantly reduced both Lp-PLA2 mass and activity.
本荟萃分析的目的是确定他汀类药物治疗是否能降低脂蛋白磷脂酶A2（Lp-PLA2）的质量浓度和/或活性。
使用医学主题词（MESH）术语和关键词检索PubMed、Scopus、科学网、临床试验.gov和谷歌学术数据库。纳入荟萃分析的是采用平行或交叉设计，研究他汀类药物对Lp-PLA2质量和/或活性影响的随机对照试验（RCT）。
在256篇文章中，选择了10项RCT进行荟萃分析。他汀类药物治疗显著降低了Lp-PLA2的质量（加权均数差[WMD] -44.46 ng/mL；95%置信区间[CI] -59.01，-29.90；p<0.001；I² = 93%）和活性（WMD -39.37 nmol/min/mL；95%CI -69.99，-8.75；p = 0.01；I² = 100%）。敏感性分析对Lp-PLA2质量是稳健的，对两项关于Lp-PLA2活性的研究也是阳性的。
他汀类药物治疗显著降低了Lp-PLA2的质量和活性。
